FAQFAQ   SearchSearch   MemberlistMemberlist   UsergroupsUsergroups 
 ProfileProfile   PreferencesPreferences   Log in to check your private messagesLog in to check your private messages   Log inLog in 
Forum index » diseases » cancer
RECIST criteria offer a simplified, conservative, extraction of imaging data for wide application in clinical trials
Post new topic   Reply to topic Page 1 of 1 [1 Post] View previous topic :: View next topic
Author Message
J
medicine forum Guru


Joined: 29 Apr 2005
Posts: 612

PostPosted: Sat Jul 15, 2006 5:41 pm    Post subject: RECIST criteria offer a simplified, conservative, extraction of imaging data for wide application in clinical trials Reply with quote

http://imaging.cancer.gov/clinicaltrials/imaging/

Imaging Response Criteria


Since the year 2000, an international committee promulgated unified,
easily applicable criteria for measuring tumor response using X-ray, CT
and MRI which is known as Response Evaluation Criteria in Solid Tumors
(RECIST). The technique is recommended but not mandatory for NCI sponsored
trials and involves formalized rules for measurement of tumor target
lesions.

Guidelines and a RECIST Quick Reference for incorporating the procedure
are available online, and detailed explanations for application of the
method in clinical trials can be found at the European Organization for
Research and Treatment of Cancer (EORTC) RECIST Web page. NCI-funded
cooperative groups are encouraged, but not required, to use RECIST
criteria.

RECIST criteria are a voluntary, international standard, and are not an
NCI standard. They are based on a simplification of former methods (WHO,
ECOG) and based on measurable disease, i.e., the presence of at least one
measurable lesion.

RECIST criteria offer a simplified, conservative, extraction of imaging
data for wide application in clinical trials. They presume that linear
measures are an adequate substitute for 2-D methods and registers four
response categories:

* CR (complete response) = disappearance of all target lesions
* PR (partial response) = 30% decrease in the sum of the longest
diameter of target lesions
* PD (progressive disease) = 20% increase in the sum of the longest
diameter of target lesions
* SD (stable disease) = small changes that do not meet above criteria

Plans call for improving on RECIST methodology by developing and
validating clinical trial-acceptable methods and standards to incorporate:

* volumetric (3D) anatomical imaging
* dynamic contrast imaging
* functional (molecular) imaging

If successful, the use of medical image data as a surrogate endpoint in
clinical trials could lead to:

* Smaller clinical trials with fewer patients
* Earlier go/no decisions on drug compounds
* Faster regulatory approval for new drugs
* Earlier use in clinical care
Back to top
Google

Back to top
Display posts from previous:   
Post new topic   Reply to topic Page 1 of 1 [1 Post] View previous topic :: View next topic
The time now is Mon Jun 18, 2018 1:30 am | All times are GMT
Forum index » diseases » cancer
Jump to:  

Similar Topics
Topic Author Forum Replies Last Post
No new posts Dear Embassies of China and Russia- Here is the NIH "Biod... Newsgroup Leader Katheen lyme 6 Fri Jul 14, 2006 12:48 am
No new posts Fear of extraction. Request dentist recommendation, San ... mr_ravi_patil@yahoo.com dentistry 3 Wed Jul 12, 2006 7:41 pm
No new posts Clinical Trials for Cancer Running Out of Volunteers - Ya... AM cancer 0 Mon Jul 10, 2006 8:15 pm
No new posts Lyme disease - Lyme borreliosis: Europe-wide coordinated ... georgia lyme 0 Fri Jun 30, 2006 9:36 pm
No new posts The comparative study of clinical therapy of secretory ot... J cancer 0 Thu Jun 29, 2006 8:03 am

Copyright © 2004-2005 DeniX Solutions SRL
Other DeniX Solutions sites: email marketing campaigns , electronics forum, Science forum, Unix/Linux blog, Unix/Linux documentation, Unix/Linux forums


Powered by phpBB © 2001, 2005 phpBB Group
[ Time: 0.0118s ][ Queries: 16 (0.0022s) ][ GZIP on - Debug on ]